PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25040794-5	2014	The importance of the TET-mediated cytosine demethylation pathway is also underscored by a recurrent mutation of isocitrate dehydrogenase 1 (IDH1) and IDH2 in hematological malignancies, whose mutation inhibits TET function through a novel oncometabolite, 2-hydroxyglutarate.	tet	22-25	isocitrate dehydrogenase (NADP(+)) 2	Homo sapiens	151-155	
32150688-6	2020	Inhibition of IDH2 in asthmatic ASM cells decreased the alpha-KG level, TET activity, and global DNA hydroxymethylation and reversed the aberrant ASM phenotypes (including decreased cell proliferation and ASM phenotypic gene expression).	tet	72-75	isocitrate dehydrogenase (NADP(+)) 2	Homo sapiens	14-18	
25040794-5	2014	The importance of the TET-mediated cytosine demethylation pathway is also underscored by a recurrent mutation of isocitrate dehydrogenase 1 (IDH1) and IDH2 in hematological malignancies, whose mutation inhibits TET function through a novel oncometabolite, 2-hydroxyglutarate.	tet	211-214	isocitrate dehydrogenase (NADP(+)) 2	Homo sapiens	151-155	
21939466-5	2011	Specifically, 2-hydroxyglutarate, the oncometabolite produced by mutant IDH1 and IDH2 proteins, has been shown to function as a competitive inhibitor of various alpha-ketoglutarate (alpha-KG)-dependent dioxygenases, including histone demethylases and members of the ten-eleven-translocation (TET) family of 5-methylcytosine (5mC) hydroxylases.	tet	292-295	isocitrate dehydrogenase (NADP(+)) 2	Homo sapiens	81-85